1

Trieste: from Research Projects to InnovationAlberto Steindler – COO eHealth & eGovernment integrated solutions

2

Friuli Venezia Giulia a Region of Excellence

3 Universities (UniTS - UniUD - SISSA)4 Science & Technology parksArea Science Park the main Italian Scientific campus Friuli Innovazione Polo Tecnologico PordenoneAgemont

30+ Research Centres and International Institutions

The FVG Region scores 8.8 researchers out of1,000 workers

ITALY 3.3EU 5.4OECD average 6.9USA 9.6Japan 10.4

3

TRIESTE City of Science

Trieste 38.5 researchers per 1,000 workers

University of TriesteSISSA International School for Advanced StudiesINAF Astronomical Observatory of TriesteLBM Marine Biological LaboratoryICTP International Centre for Theoretical PhysicsTWAS Academy of Sciences for the developing worldCIB Interuniversity Consortium for BiotechnologiesICGEB International Centre for Genetic Engineering and BiotechnologyINFN National Institute for Nuclear PhysicsICS UNIDO International Centre for Science and High Technology ELETTRA Synchtrotron and Free-electron laser lightTASC National Laboratory for Advanced Technology and NanoscienceCNR Institute for the Structure of Matter OGS National Institute for Oceanography and Geophysics

This fertile background gave birth to bright examples of excellence in local industry,

such as TBS Group

4

• Born from the research project ACMAGEST, was established in the ‘80s as an advanced clinical engineering service provider

• From 2000 it began investing in its growth abroad (esp. EU) widening its range of activities

• Leader in the services for Medical Equipment & DevicesReference player for e-Health & e-Government systems and solutions

• HQ - AREA Science Park (Trieste)

• Operates in 13 countries through over 20 subsidiaries(Austria, Belgium, China, France, Germany, India, UK, Italy, The Netherlands, Portugal, Saudi Arabia, Serbia and Spain)

• 2200+ highly qualified staff and 197,5M revenues (2011)

• 330 workshops, 45 Regional operational centres, 25 competence centres

• 300 laboratories on site, connected to more than 1.000 European and Extra-european Hospitals

• Listed on the Stock Exchange AIM Italy since 2009

TBS Group

5

TBS Group: from Trieste to Europe… and Beyond

PCS GmbHwww.pcs.at

TBS BE Telematic & Biomedical Services Bvbawww.tbsbe.com

TBS FR Telematic & Biomedical Services Sarlwww.tbsfr .com

Subitec GmbHwww.subitec .de

MSI MedServ International Deutschland GmbHwww.medservinternational .com

TBS Group S.p.A.www.tbsgroup .com

EBM Srlwww.ebm.it

Insiel Mercato S.p.Awww.insielmercato.it

TeSAN S.p.A.www.tesan .it

CRIMO Italia Srlwww.crimo.it

Caribel srlwww.caribel.it

SLT srlwww.slt.eu.com

Surgical Technologies BVwww.surgical .nl

TBS PT (STB Serviços Telemáticos e Biomédicos Unipessoal LDA)www.tbspt.com

TBS G.B. Telematic & Biomedical Services Ltdwww.tbsgb.com

TBS Group, Area Science Park, Trieste

Arab Health TBS Saudi Sinopharm TBS (China)

TBS ES (Telematic & Biomedical Services SL)www.tbses.com

MNE Technologies Private Ltd.www.mneindia.com

Tesan Televita srlwww.tesantelevita.it

6

Why Innovate? …to create VALUE

The WHY of innovation is simple: change is accelerating and we don’t know what’s coming in the future: we must innovate to both prepare for change

…and …to make change.

CARE(Social and Healthcare Systems)

€ $ £

CHALLENGES

TOOLS

Aging Society

Chronic diseases

Medical – Bio - informatics

Biotech

Nanotech

7

• New products/services

• New “state of the art” technologies

• New business models & sales partnerships

• Intensified cooperation with other businesses and PROs (Public Research Organizations)

• Enhance culture within the company and outwards:- integrated care- genomics, proteomics, nutrigenomics

(and other –omics) and personalized medicine

R&D – Overall Aims

INNOVATION

8

R&D and INNOVATION in TBS

• Process innovation to optimize the way in which products and services are created

• Develop new Telemedicine product & services

• Develop new medical & bio – informatics solutions for the personalization of medicine (integration of clinical and genetic data)

• Innovation of processes to better fulfill or even anticipate the requirements of our customer

GOAL strengthen our position as a reference player in the markets and as a crucial actor for the new scopes of healthcare - such as the Proactive Medicine - increasing the quality of social and healthcare services provided to the population

Our latest and most significant R&D projects

CASE EXAMPLES

10

CHRONIUS: management of chronic patients (COPD and Kidney disease) at their home. Several tools such as wearable sensors, and others for lifestyle monitoring, smart clinical decision support system.

FEARLESS: detecting potential situation of risk in domestic environment with automatic alarms. Fall alarms, imaging analysis alarms; flood, gas, smoke alarms.

Telemedicine … we are not Dreaming only!

I-DON’T-FALL: ICT Platform for the prevention and management of falls with personalized solutions for vulnerable patients.

HEALTH AT HOME: design and development of a home monitoring system for Chronic Heart Failure patients.

IN PISTA: consolidation and extension of support standards to interoperability and integration of social and health information systems.

11

Pharma PHI: integrated molecular data EPR for more personalized and thus efficient drugs.

SYMPAR: EPR for the management of neurodegenerative disease protocols (Parkinson).

D.NAMICA: IT integrated platform for the personalized medicine (genothypic and phenotypic data).

Nutraceutics & Nutrigenomics a path to personalized diet: functional foods and services that improve the health of individuals and reduce the occurrence of disease.

Medical & Bio- Informatics

12

phi-Technology: open source platform

for the design-generation-implementation of healthcare web applications (process/model

driven & sevice oriented architecture)

25+ running contracts

Further effects of R&D

Telemedicine in the VCOVerbania Cusio OssolaMulti-pathology unified platform The first real-time Telemedicine experience in the Piedmont Region for 300 home patients affected by cancer- diabetes - COPD – Heart Failure.

Genotype and Phenotype integrated EPR

Telemedicine in the Veneto Region telemonitoring of people who live situations of social and/or health care risk (2,400 users), electronic detection falls (1,200 users), remote monitoring vital signs (1,200 users) now 246 active users.

NHS’ Whole System Demonstrator Programme (partecipation in KENT)the largest randomized control trial of telehealth and telecare in the world, involving 6191 patients (diabetes, Heart Failure and COPD) and 238 GP.

13

CLINICAL PATHWAYS: to standardize care processes and improve quality in healthcare.

INTEGRATED CARE: to overcome the fragmented delivery of health and social services - more coordinated and integrated forms of care provision (diagnosis, treatment, care, rehabilitation and health promotion).

PROACTIVE MEDICINE: shift from reactive medicine (waits for the disease and then provides treatment)

Proactive medicine provides a platform for maximizing prevention and aims at treating the root causes of the disease process improving the care of chronic disease and boosting the self care model

What’s coming next?

14

R&D plays an important role leveraging the INNOVATION process which is increasingly vital to current and future profits.

Innovation brings new or improved products and services to the market place (more customers, more satisfied customers).

Innovation allows to participate in new markets.

It results in high quality jobs, elevating knowledge among employees.

R&D provides a better position to achieve and maintain competitive advantage in the increasingly challenging global market place.

R&D IS OUR EYE ON THE FUTURE

So… why is R&D so crucial? Our experience…

15

“The greatest discovery of my generation is that human beings can alter their lives by

altering their attitudes of mind.”

WILLIAM JAMES 1842 - 1910

Free reconstruction from “Metamorphose” by M.C. Escher